Northwell Health has spent more than $30 million since the beginning of the pandemic on COVID-19 testing equipment and lab supplies, including a variety of new automated machines this summer to ensure both diagnostic and antibody testing will continue as part of a rapid and uninterrupted process in the event of another surge
A Northwell Health Labs technologist inserts specimens into a diagnostic testing machine. (Credit: Northwell Health)
Despite low positivity rates and prudent public action to prevent a recurrence of coronavirus disease 2019 (COVID-19) in New York State, Northwell Health Labs announced that it has aggressively invested in multiple testing platforms to both increase its ability to ramp up volume and mitigate supply chain disruptions should a second wave strike.
Northwell Health has spent more than $30 million since the beginning of the pandemic on COVID-19 testing equipment and lab supplies, including a variety of new automated machines this summer to ensure both diagnostic and antibody testing will continue as part of a rapid and uninterrupted process in the event of another surge. The lab processes tests for 19 Northwell hospitals, 52 urgent care centers and more than 800 outpatient facilities – along with the needs of strategic partners – across Long Island, New York City and the Hudson Valley.
“Our goal has been to deploy at scale as much testing as possible, as quickly as possible, so we were among the first labs to implement, validate and evaluate performance characteristics for most of these tests,” said Dwayne Breining, MD, executive director of Northwell Health Labs. “Early in the pandemic, it was unclear which manufacturer would be able to supply quality testing at scale, so we ran with them all. As various supply chain issues have emerged, maintaining multiple testing platforms has been a successful mitigation strategy.”
As part of the largest investment in COVID-19 testing by a hospital-based lab in the nation, Northwell Health recently purchased high-throughput diagnostic testing analyzers from Hologic, Roche and Abbott, as well as cartridge-type tests from Genmark, Cepheid, Diasorin, Biomeme and Abbott. Northwell also is using best-in-class, in-lab, “wet” antibody chemistry tests from Roche, Ortho, Abbott, EuroImmune, Diasorin and others.
Northwell Labs is currently processing about 7,000 molecular nucleic acid amplification tests and an additional 3,000 antibody tests per day with the capability of increased volume. Labs is also focused on eliminating false positives, which at this stage of the pandemic has the potential to close classrooms and schools, by developing a two-step algorithm for retesting isolated positives versus clustered positives.
“Most testing today is for screening purposes, so we need to mitigate the potential effects of sporadic false-positive results,” said James Crawford, MD, senior vice president of laboratory services at Northwell. “These are more likely to occur now that the New York area positivity rate is below 1 percent.”
Northwell Health Labs is committed to providing ongoing testing for the duration of the pandemic, no matter the length or severity. Anyone in need of a COVID-19 test can get one though Northwell Health-GoHealth Urgent Care, Northwell Health Labs patient service center (with a doctor’s prescription) or via in-home testing through the LabFly app.
Source: Company Press Release